SINGAPORE, Dec 6 (Bernama-BUSINESS WIRE) — RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis. Building on the strength of collaboration with National University of Singapore, this fresh investment accentuates RxCell’s resolute drive to revolutionize age-related disease treatment.
Furthermore, RxCell is gearing up for a substantial second capital raise of $15,000,000 in Q4 2023. This upcoming fundraise is strategically designed to secure the necessary resources, propelling the company forward through its promising IND (Investigational New Drug) application testing and process.